Authors

David J. Hughes, Royal College of Surgeons in Ireland
Veronika Fedirko, Emory University
Mazda Jenab, International Agency for Research on Cancer, France
Lutz Schomburg, Charite - Universitatsmedizin Berlin
Catherine Meplan, Newcastle University
Heinz Freisling, International Agency for Research on Cancer, France
H B(as) Bueno-de-Mesquita, Imperial College London
Sandra Hybsier, Charite - Universitatsmedizin Berlin
Niels-Peter Becker, Charite - Universitatsmedizin Berlin
Magdalena Czuban, Charite - Universitatsmedizin Berlin
Anne Tjonneland, Danish Cancer Society Research Centre
Malene Outzen, Danish Cancer Society Research Centre
Marie-Christine Boutron-Ruault, Universite Paris Sud
Antoine Racine, Universite Paris Sud
Nadia Bastide, Universite Paris Sud
Tilman Kuhn, German Cancer Research Center
Rudolf Kaaks, German Cancer Research Center
Dimitrios Trichopoulos, Harvard School of Public Health
Antonia Trichopoulou, Hellenic Health Foundation
Pagona Lagiou, University of Athens Medical School
Salvatore Panico, Federico II University, Naples
Petra H. Peeters, University Medical Centre Utrecht
Elisabete Weiderpass, University of Tromso
Guri Skeie, University of Tromso
Engeset Dagrun, University of Tromso
Maria-Dolores Chirlaque, Murcia Regional Health Authority
Maria-Jose Sanchez, Navarre Public Health Institute
Eva Ardanaz, Navarre Public Health Institute
Ingrid Ljuslinder, Umea University
Maria Wennberg, Umea University
Kathryn E. Bradbury, University of Oxford
Paolo Vineis, Imperial College London
Alessio Naccarati, Human Genetics Foundation, Italy
Domenico Palli, Cancer Research and Prevention Institute, Florence
Heiner Boeing, German Institute of Human Nutrition
Kim Overvad, Aarhus University
Miren Dorronsoro, BioDonostia Research Institute, Spain
Paula Jakszyn, Catalan Institute of Oncology
Amanda J. Cross, Imperial College London
Jose Ramon Quiros, Public Health Directorate of Asturias
Magdalena Stepien, International Agency for Research on Cancer, France
So Yeon Kong, International Agency for Research on Cancer, France
Talita Duarte-Salles, International Agency for Research on Cancer, France
Elio Riboli, Imperial College London
John E. Hesketh, Newcastle University

Peer Reviewed

1

Document Type

Article

Publication Date

7-2014

Keywords

Selenium, Selenium Status, Colorectal Neoplasms, Selenoprotein P, Prospective Cohort

Comments

This is the pre-peer reviewed version of the following article: Hughes DJ, Fedirki V, Jenab M, Schomburg L, Meplan C, Freisling H, Bueno-de-Mesquita HB, Hybsier S, Becker NP, Czuban M, Tjonneland A, Outzen M, Boutron-Ruault MC, Racine A, Bastide N, Kuhn T, Kaaks R, Trichopoulos D, Trichopoulou A, Lagiou P, Panico S, Peeters P, Weiderpass E, Skeie G, Dagrun E, Chirlaque MD, Sanchez MJ, Ardanaz E, Ljuslinder I, Wennberg M, Bradbury KE, Vineis P, Naccarati A, Palli D, Boeing H, Overvad K, Dorronsoro M, Jakszyn P, Cross AJ, Quiros JR, Stepien M, Kong SY, Duarte-Salles T, Riboli E, Hesketh JE. Selenium Status is Associated with Colorectal Cancer risk in the European Prospective Investigation of Cancer and Nutrition Cohort. International Journal of Cancer. Article first published online: 21 JUL 2014, which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1002/ijc.29071/pdf

DOI: 10.1002/ijc.29071

Abstract

Suboptimal intakes of the micronutrient selenium (Se) are found in many parts of Europe. Low Se status may contribute to colorectal cancer (CRC) development. We assessed Se status by measuring serum levels of Se and Selenoprotein P (SePP) and examined the association with CRC risk in a nested case-control design (966 CRC cases; 966 matched controls) within the European Prospective Investigation into Cancer and Nutrition. Se was measured by total reflection X-ray fluorescence and SePP by immunoluminometric sandwich assay. Multivariable incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression. Respective mean Se and SePP levels were 84.0 µg/L and 4.3 mg/L in cases and 85.6 µg/L and 4.4 mg/L in controls. Higher Se concentrations were associated with a non-significant lower CRC risk (IRR = 0.92, 95%CI: 0.82-1.03 per 25 µg/L increase). However, sub-group analyses by sex showed a statistically significant association for women (Ptrend = 0.032; per 25 µg/L Se increase, IRR = 0.83, 95%CI: 0.70-0.97) but not for men. Higher SePP concentrations were inversely associated with CRC risk (Ptrend = 0.009; per 0.806 mg/L increase, IRR = 0.89, 95%CI: 0.82-0.98) with the association more apparent in women (Ptrend = 0.004; IRR = 0.82, 95%CI: 0.72-0.94 per 0.806 mg/L increase) than men (Ptrend = 0.485; IRR = 0.98, 95%CI: 0.86-1.12 per 0.806 mg/L increase). The findings indicate that Se status is suboptimal in many Europeans and suggest an inverse association between CRC risk and higher serum Se status, which is more evident in women.

Disciplines

Physics | Physiology

Citation

Hughes DJ, Fedirki V, Jenab M, Schomburg L, Meplan C, Freisling H, Bueno-de-Mesquita HB, Hybsier S, Becker NP, Czuban M, Tjonneland A, Outzen M, Boutron-Ruault MC, Racine A, Bastide N, Kuhn T, Kaaks R, Trichopoulos D, Trichopoulou A, Lagiou P, Panico S, Peeters P, Weiderpass E, Skeie G, Dagrun E, Chirlaque MD, Sanchez MJ, Ardanaz E, Ljuslinder I, Wennberg M, Bradbury KE, Vineis P, Naccarati A, Palli D, Boeing H, Overvad K, Dorronsoro M, Jakszyn P, Cross AJ, Quiros JR, Stepien M, Kong SY, Duarte-Salles T, Riboli E, Hesketh JE. Selenium Status is Associated with Colorectal Cancer risk in the European Prospective Investigation of Cancer and Nutrition Cohort. International Journal of Cancer. Article first published online: 21 JUL 2014. DOI: 10.1002/ijc.29071

DOI Link

10.1002/ijc.29071

Share

COinS